TetanusPhase 1/2NCT06939777
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants
A Phase 1/2 study testing SNA02-48, HTIG and Tetanus Toxoid in people with Tetanus, run by Sinovac Life Sciences Co., Ltd. at 1 site in China.
Trial summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the full human anti-tetanus toxin monoclonal antibody SNA02-48 injection and compare the Tetanus-antibody levels and safety of SNA02-48 with human tetanus immunoglobulin (HTIG) in Chinese adult participants. Read more about this study
- Who is it for?
- Ages 18 to 59 yearsHealthy volunteers can take part
- Conditions the study is for
- Tetanus
- What is being tested?
- SNA02-48, HTIG and Tetanus Toxoid
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 255 participants
- Where
- 1 siteChina
- Study dates
- 28 Apr 2025to 30 Mar 2026
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 59 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male or female, 18-59 years of age；
- Participants have the ability to understand and agree to sign the informed consent form；
- Male participants with a weight of≥50.0kg; Female participants with a weight of ≥ 45.0kg and the weight of both men and women≤90 kg, 18.5 kg/m2≤BMI < 24.0 kg/m2;
- Participants of childbearing potential and their sexual partners voluntarily adopt effective contraceptive measures from the date of signing the informed consent form until 6 months after the administration of the investigational drug, and have no plans to donate sperm or ova during this period.
Who cannot join
- Previous history of tetanus infection;
- Has received tetanus vaccines or vaccines containing tetanus toxoid antigen (DTP, DT, meningococcal conjugate vaccine, etc.) within the last 10 years, or has received a tetanus immunoglobulin or tetanus antitoxin within the previous 6 months;
- Participants with positive tetanus antibody IgG test results during the screening period；
- Participants who are known to be allergic to experimental drugs (including excipients, HTIG, and other therapeutic monoclonal antibodies), or who suffer from severe allergic diseases, may damage the safety of the participants by the judgment of the investigator;
- Positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV antibody (HIV Ab), or Treponema pallidum antibody (TP Ab);
- Physical examinations, vital signs, electrocardiograms (ECGs), laboratory tests, or other test results during the screening or baseline period that are judged by the investigator to be abnormal and clinically significant;
Show all 26Show fewer
- Participants with uncontrolled chronic or severe disease history, including but not limited to cardiovascular disease, hematological system disease, hepatobiliary or renal diseases, gastrointestinal diseases, respiratory disease, malignant tumor, history of major organ transplantation, which may affect the pharmacokinetic profiles or safety evaluation of the investigational drug as determined by the investigator;
- Autoimmune diseases or immunodeficiency disorders (including but not limited to systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), autoimmune thyroid diseases (AITD), asplenia, functional asplenia, or human immunodeficiency virus infection (HIV));
- Participants with coagulation dysfunction that is abnormal and clinically significant as determined by the investigator (e.g., coagulation factor deficiency, platelet abnormalities);
- Current or past history of severe neurological disorders (including but not limited to epilepsy, convulsions, or seizures) or psychiatric disorders, or a family history of psychiatric disorders;
- Have a history of drug abuse or dependence or recreational drug use within 2 years prior to screening, or have a positive urine drug abuse screening before enrollment;
- Participants who have received immunosuppressants or other immunomodulatory therapies (e.g., prednisone≥20 mg/day or equivalent) for≥14 days within the 6 months, cytotoxic therapy, or plan to receive such treatments during the trial period;
- Participants who have received immune globulin or other blood products within the 6 months, or plan to receive such treatments during the trial period;
- Participants who have donated >400 ml of blood or experienced significant blood loss >400 ml within 3 months prior to drug administration, or donated plasma or platelets within 1 month prior to drug administration;
- Participants who have participated in other drug or medical device clinical trials within 3 months prior to screening, or plan to participate in other clinical trials during the trial period;
- Participants who have smoked≥5 cigarettes per day within 3 months prior to screening;
- Participants who have consumed >14 alcohol units per week within 3 months prior to screening (1 alcohol unit = 14 grams of pure alcohol = 360 ml beer, 150 ml wine, or 45 ml distilled spirits/liquor);
- Acute diseases, acute exacerbation of chronic diseases or surgical history within 4 weeks prior to screening;
- Receipt of live attenuated vaccines within 4 weeks prior to screening or subunit/inactivated vaccines (or other vaccine types) within 7 days prior to screening;
- Receipt of any prescription medications, over-the-counter (OTC) medications supplements, or functional vitamins within 14 days prior to screening;
- Participants who have consumed special diets (e.g., grapefruit, etc.) or engaged in strenuous exercise, or have other factors affecting drug absorption, distribution, metabolism, or excretion within 14 days prior to screening;
- Women in pregnancy or lactation or those with a positive pregnancy test;
- Participants who have consumed any caffeine-containing or tea within 24 hours prior to investigational drug administration;
- Ear temperature during the screening or baseline period is> 37.6℃;
- Skin lesions (including inflammation, ulcers, rashes, or scars) at the target injection site that may interfere with drug administration or observation of local reactions;
- According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Double-Blind, Controlled, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the full human anti-tetanus toxin monoclonal antibody SNA02-48 injection and compare the Tetanus-antibody levels and safety of SNA02-48 with human tetanus immunoglobulin (HTIG) in Chinese adult participants.
Read the detailed description
This is a randomized, double-blind, placebo/active-controlled phase I/II study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SNA02-48 Injection in Chinese adult participants.
In the phase I portion of the study, 30 adult participants will be sequentially enrolled into three cohorts. Each participant will receive a single intramuscular (IM) dose of either SNA02-48 or placebo, depending on the cohort to which they are assigned. The phase I part will last for 105 days following the assessments of safety, PK, PD and ADA.
In the phase II portion of the study, 225 adult participants will be enrolled and randomly assigned to nine groups.The phase II part will last for 105 days following the assessments of safety, PK, PD and ADA.
- Conditions
- Tetanus
- Being tested
- SNA02-48, Placebo, HTIG, Tetanus Toxoid
- Medical subject headings
- Tetanus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SNA02-48Biological
intramuscular injection
PlaceboBiological
intramuscular injection
HTIGBiological
intramuscular injection
Tetanus ToxoidBiological
intramuscular injection
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1:low-dose SNA02-48/placebo (Phase I) | Experimental | Participants will be randomly assigned to receive either low-dose SNA02-48 or placebo. Receives: Biological: SNA02-48; Biological: Placebo |
| Cohort 2: medium-dose SNA02-48/placebo (Phase I) | Experimental | Participants will be randomly assigned to receive either medium-dose SNA02-48 or placebo. Receives: Biological: SNA02-48; Biological: Placebo |
| Cohort 3: high-dose SNA02-48/placebo (Phase I) | Experimental | Participants will be randomly assigned to receive either high-dose SNA02-48 or placebo. Receives: Biological: SNA02-48; Biological: Placebo |
| Group A :low-dose SNA02-48 + placebo (Phase II) | Experimental | Participants will receive a single intramuscular (IM) gluteal injection of low-dose SNA02-48 and a single IM deltoid injection of placebo Receives: Biological: SNA02-48; Biological: Placebo |
| Group B : medium-dose SNA02-48 + placebo (Phase II) | Experimental | Participants will receive a single IM gluteal injection of medium-dose SNA02-48 and a single IM deltoid injection of placebo Receives: Biological: SNA02-48; Biological: Placebo |
| Group C : high-dose SNA02-48 + placebo (Phase II) | Experimental | Participants will receive a single IM gluteal injection of high-dose SNA02-48 and a single IM deltoid injection of placebo Receives: Biological: SNA02-48; Biological: Placebo |
| Group D : low-dose SNA02-48 + Tetanus Toxoid (Phase II) | Experimental | Participants will receive a single IM gluteal injection of low-dose SNA02-48 and a single IM deltoid injection of Tetanus Toxoid（TT） Receives: Biological: SNA02-48; Biological: Tetanus Toxoid |
| Group E : medium-dose SNA02-48 + Tetanus Toxoid (Phase II) | Experimental | Participants will receive a single IM gluteal injection of medium-dose SNA02-48 and a single IM deltoid injection of Tetanus Toxoid（TT） Receives: Biological: SNA02-48; Biological: Tetanus Toxoid |
| Group F : high-dose SNA02-48 + Tetanus Toxoid (Phase II) | Experimental | Participants will receive a single IM gluteal injection of high-dose SNA02-48 and a single IM deltoid injection of Tetanus Toxoid（TT） Receives: Biological: SNA02-48; Biological: Tetanus Toxoid |
| Group G : placebo + Tetanus Toxoid (Phase II) | Placebo comparator | Participants will receive a single IM gluteal injection of placebo and a single IM deltoid injection of Tetanus Toxoid（TT） Receives: Biological: Placebo; Biological: Tetanus Toxoid |
| Group H : Human tetanus immunoglobulin(HTIG) + placebo (Phase II) | Active comparator | Participants will receive a single IM gluteal injection of Human tetanus immunoglobulin(HTIG) and a single IM deltoid injection of placebo Receives: Biological: Placebo; Biological: HTIG |
| Group I : Human tetanus immunoglobulin(HTIG) + Tetanus Toxoid（TT） (Phase II) | Active comparator | Participants will receive a single IM gluteal injection of Human tetanus immunoglobulin(HTIG) and a single IM deltoid injection of Tetanus Toxoid（TT） Receives: Biological: HTIG; Biological: Tetanus Toxoid |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of adverse reactions
Measured: Up to 105 days
The increase in serum tetanus antibody levels from baseline at 12 hours post-administration
Measured: 12 hours after administration
Secondary outcomes (12)
Time of maximum plasma concentration (Tmax)
Measured: Up to 105 days
Peak plasma concentration(Cmax)
Measured: Up to 105 days
Terminal half-life (T1/2)
Measured: Up to 105 days
clearance(CL)
Measured: Up to 105 days
Apparent Volume of Distribution(Vd)
Measured: Up to 105 days
Area under the plasma concentration time curve (AUC)
Measured: Up to 105 days
Terminal Elimination Rate Constant(λz)
Measured: Up to 105 days
Mean Residence Time (MRT)
Measured: Up to 105 days
Serum tetanus antibody level
Measured: Up to 105 days
Positive rate of serum tetanus antibody
Measured: Up to 105 days
The increase in serum tetanus antibody levels from baseline after administration
Measured: Up to 105 days
Incidence of anti-drug antibody (ADA) and neutralizing antibody (Nab)
Measured: Up to 105 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Apr 2025
- Study start28 Apr 2025
- Primary completion8 Dec 2025
- Study completion30 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for TetanusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 255 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sinovac Life Sciences Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Wei Hu, Principal investigator, The Second Hospital of Anhui Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06939777
- Sponsor's protocol ID
- PRO-SNA02-48-1001
- Status last verified
- Jun 2026
- First submitted
- 15 Apr 2025
- Last updated
- 3 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No